钠-葡萄糖共转运蛋白2抑制剂对老年2型糖尿病患者发生肌肉减少症的影响

宋宝娜; 林萍; 王琴

doi:10.16766/j.cnki.issn.1674-4152.003039

钠-葡萄糖共转运蛋白2抑制剂对老年2型糖尿病患者发生肌肉减少症的影响

doi: 10.16766/j.cnki.issn.1674-4152.003039

宋宝娜¹,
林萍^2, ,,
王琴²

1.
浙江中医药大学第四临床医学院，浙江杭州 310053
2.
杭州市第三人民医院老年科，浙江杭州 310009

基金项目:

浙江省杭州市卫生计生科技计划重点项目 2018Z05

浙江省医药卫生科技计划面上项目 2019KY502

杭州市医学重点学科建设项目杭卫发[2021]21号

详细信息

通讯作者:
林萍，E-mail: yjlp1@163.com

中图分类号: R587.1 R592
计量
- 文章访问数: 308
- HTML全文浏览量: 114
- PDF下载量: 13
- 被引次数: 0
出版历程
- 收稿日期: 2022-02-10
- 网络出版日期: 2023-08-26

Effect of sodium-glucose cotransporter 2 inhibitor on sarcopenia in elderly patients with type 2 diabetes

SONG Baona¹,
LIN Ping^{2
, ,},
WANG Qin²

1.
The Fourth Clinical Medical College of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang 310053, China

摘要

摘要: 2型糖尿病是老年人常见的疾病之一，随着年龄的增加发病率增高。肌肉减少症简称肌少症，是一种与增龄相关的临床综合征。研究表明，肌少症在老年2型糖尿病患者中的发病率逐年增高。2型糖尿病合并肌少症的发病机制主要有：胰岛素抵抗、慢性炎症、氧化应激、线粒体功能障碍、周围神经病变及损伤、降糖药物的使用等。多种降糖药物例如双胍类(biguanides)、噻唑烷二酮类(thiazolidinediketones)、二肽激肽酶-4抑制剂(dipeptidyl peptidase-4 inhibitors，DPP-Ⅳ抑制剂)、胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist，GLP-1RA)、钠-葡萄糖共同转运体2抑制剂(sodium-glucose cotransporter-2 inhibitors, SGLT-2i)等均对肌少症的发生有影响。随着SGLT-2i在降糖治疗及心血管疾病治疗中的广泛应用，笔者发现，其对肌少症也有重要影响。SGLT-2i在老年2型糖尿病患者的使用过程中，能够优化人体结构，减少脂肪量但不会影响肌肉含量，不会增加骨折的发生率；可以通过肌肉和脂肪的调节与转录、提高氧化磷酸化及控制炎症等方面延缓肌少症的发生；可通过影响中枢神经系统，使患者的主动摄食量增加，从营养不良层面减少肌少症发生的风险。因此，SGLT-2i应用于老年2型糖尿病患者，不仅能起到降糖、保护心血管的作用，对延缓肌少症的发生也有重要的意义。SGLT-2i的使用对老年2型糖尿病合并肌少症患者的治疗来说，或许可以带来新思路、新靶点。
- 钠-葡萄糖共转运蛋白2抑制剂 /
- 老年2型糖尿病 /
- 肌肉减少症
Abstract: Type 2 diabetes is one of the common diseases of the elderly, and the incidence increases with the increase of age. Sarcopenia, or sarcopenia, is also a clinical syndrome associated with aging. Studies have shown that the incidence of sarcopenia in elderly patients with type 2 diabetes is increasing year by year. The pathogenesis of type 2 diabetes combined with sarcopenia mainly includes insulin resistance, chronic inflammation, oxidative stress, mitochondrial dysfunction, peripheral neuropathy and injury, and the use of hypoglycemic drugs. Many hypoglycemic drugs, such as biguanides, thiazolidinediketones, dipeptidyl peptiase-4 inhibitors (DPP-Ⅳ inhibitor), glucagon-like peptide-1 receptor agonist (GLP-1RA), sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and other inhibitors have influence on the occurrence of sarcopenia. With the wide application of SGLT-2i in hypoglycemic treatment and cardiovascular disease treatment, the author found that it also has an important impact on sarcopenia. When used in elderly patients with type 2 diabetes, SGLT-2i can optimize the body structure and reduce fat without affecting muscle content or increasing the incidence of fracture. It can delay the occurrence of sarcopenia through the regulation and transcription of muscle and fat, improve oxidative phosphorylation and control inflammation. By influencing the central nervous system, the active food intake of patients can be increased and the risk of sarcopenia can be reduced from the level of malnutrition. Therefore, the application of SGLT-2i in elderly patients with type 2 diabetes can not only play a role in hypoglycemia and cardiovascular protection, but also has important significance in delaying the occurrence of sarcopenia. The application of SGLT-2i may bring new ideas and targets for the treatment of elderly patients with type 2 diabetes complicated with sarcopenia.
- Sodium and glucose co-transporter 2 inhibitor /
- Geriatric type 2 diabetes /
- Sarcopenia

HTML全文

参考文献(43)

[1]	国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南(2021年版)[J]. 中华老年医学杂志, 2021, 40(1): 1-33. doi: 10.3760/cma.j.issn.0254-9026.2021.01.001
[2]	LI Y, TENG D, SHI X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020, 369: m997. DOI: 10.1136/bmj.m997.
[3]	AWAD S F, Al-MAWALI A, Al-LAWATI J A, et al. Forecasting the type 2 diabetes mellitus epidemic and the role of key risk factors in Oman up to 2050: mathematical modeling analyses[J]. J Diabetes Investig, 2021, 2(7): 1162-1174.
[4]	PAR A, HEGYI J P, VANCSA S, et al. Sarcopenia-2021: pathophysiology, diagnosis, therapy[J]. Orv Hetil, 2021, 162(1): 3-12. doi: 10.1556/650.2021.32015
[5]	刘娟, 丁清清, 周白瑜, 等. 中国老年人肌少症诊疗专家共识(2021)[J]. 中华老年医学杂志, 2021, 40(8): 943-952. doi: 10.3760/cma.j.issn.0254-9026.2021.08.001 LIU J, DING Q Q, ZHOU B Y, et al. Chinese expert consensus on diagnosis and treatment for elderly with sarcopenia(2021)[J]. Chinese Journal of Geriatrics, 2021, 40(8): 943-952. doi: 10.3760/cma.j.issn.0254-9026.2021.08.001
[6]	刘利利, 赵柯湘, 罗成, 等. 重庆市主城区中老年体检人群肌肉减少症患病率调查及危险因素分析[J]. 中华全科医学, 2019, 17(10): 1762-1767. doi: 10.16766/j.cnki.issn.1674-4152.001050 LIU L L, ZHAO K X, LUO C, et al. Prevalence and risk factors of sarcopenia in urban area of Chongqing[J]. Chinese Journal of General Practice, 2019, 17(10): 1762-1767. doi: 10.16766/j.cnki.issn.1674-4152.001050
[7]	FENG L, GAO Q, HU K, et al. Prevalence and risk factors of sarcopenia in patients with diabetes: a meta-analysis[J]. J Clin Endocrinol Metab, 2022, 107(5): 1470-1483. doi: 10.1210/clinem/dgab884
[8]	TAKAHASHI F, HASHIMOTO Y, KAJI A, et al. Sarcopenia is associated with a risk of mortality in people with type 2 diabetes mellitus[J]. Front Endocrinol (Lausanne), 2021, 12: 783363. DOI: 10.3389/fendo.2021.783363.
[9]	MU Z J, FU J L, SUN L N, et al. Associations between homocysteine, inflammatory cytokines and sarcopenia in Chinese older adults with type 2 diabetes[J]. BMC Geriatr, 2021, 21(1): 692. doi: 10.1186/s12877-021-02622-y
[10]	IZZO A, MASSIMINO E, RICCARDI G, et al. A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors[J]. Nutrients, 2021, 13(1): 183. doi: 10.3390/nu13010183
[11]	MASSIMINO E, IZZO A, RICCARDI G, et al. The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms[J]. Cells, 2021, 10(8): 1958. doi: 10.3390/cells10081958
[12]	CHEN F, XU S, WANG Y, et al. Risk factors for sarcopenia in the elderly with type 2 diabetes mellitus and the effect of metformin[J]. J Diabetes Res, 2020, 2020: 3950404. DOI: 10.1155/2020/3950404.
[13]	HASSAN F E, SAKR H I, MOHIE P M, et al. Pioglitazone improves skeletal muscle functions in reserpine-induced fibromyalgia rat model[J]. Ann Med, 2021, 53(1): 1032-1040.
[14]	TSURUTANI Y, NAKAI K, INOUE K, et al. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: a multicentre, randomized, prospective, open-label, active-controlled study[J]. Diabetes Obes Metab, 2018, 20(11): 2675-2679. doi: 10.1111/dom.13421
[15]	HONG Y, LEE J H, JEONG K W, et al. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy[J]. J Cachexia Sarcopenia Muscle, 2019, 10(4): 903-918. doi: 10.1002/jcsm.12434
[16]	GIUGLIANO D, LOGO M, SCAPPATICCIO L, et al. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes[J]. Cardiovasc Diabetol, 2021, 20(1): 17. doi: 10.1186/s12933-021-01213-w
[17]	TILINCA M C, TIUCA R A, TILEA I, et al. The SGLT-2 inhibitors in personalized therapy of diabetes mellitus patients[J]. J Pers Med, 2021, 11(12): 1249. doi: 10.3390/jpm11121249
[18]	SANO M, MEGURO S, KAWAI T, et al. Increased grip strength with sodium-glucose cotransporter 2[J]. J Diabetes, 2016, 8(5): 736-737. doi: 10.1111/1753-0407.12402
[19]	KURIYAN R. Body composition techniques[J]. Indian J Med Res, 2018, 148(5): 648-658. doi: 10.4103/ijmr.IJMR_1777_18
[20]	SARGEANT J A, HENSON J, KING J A, et al. A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans[J]. Endocrinol Metab (Seoul), 2019, 34(3): 247-262. doi: 10.3803/EnM.2019.34.3.247
[21]	XU H Q, LIU J M, ZHANG X, et al. Estimation of skeletal muscle mass by bioimpedance and differences among skeletal muscle mass indices for assessing sarcopenia[J]. Clin Nutr, 2021, 40(4): 2308-2318. doi: 10.1016/j.clnu.2020.10.021
[22]	WALOWSKI C O, BRAUN W, MAISCH M J, et al. Reference values for skeletal muscle mass-current concepts and methodological considerations[J]. Nutrients, 2020, 12(3): 755. doi: 10.3390/nu12030755
[23]	SASAKI T, SUGAWARA M, FUKUDA M. SGLT2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT Study with luseogliflozin[J]. J Diabetes Investig, 2019, 10(1): 108-117. doi: 10.1111/jdi.12851
[24]	KAMEI S, IWAMOTO M, KAMEYAMA M, et al. Effect of tofogliflozin on body composition and glycemic control in Japanese subjects with type 2 diabetes mellitus[J]. J Diabetes Res, 2018, 2018: 6470137. DOI: 10.1155/2018/6470137.
[25]	MATSUBA I, TAKIHATA M, TAKAI M, et al. Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2021, 23(12): 2614-2622. doi: 10.1111/dom.14508
[26]	INOUE H, MORINO K, UGI S, et al. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: a randomized clinical trial[J]. J Diabetes Investig, 2019, 10(4): 1012-1021. doi: 10.1111/jdi.12985
[27]	TOBITA H, SATO S, MIYAKE T, et al. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study[J]. Curr Ther Res Clin Exp, 2017, 87: 13-19. doi: 10.1016/j.curtheres.2017.07.002
[28]	SAKAMOTO M, GOTO Y, NAGAYAMA A, et al. Two-year administration of sodium-glucose co-transporter 2 inhibitor brought about marked reduction of body fat independent of skeletal muscle amount or glycemic improvement in Japanese patients with type 2 diabetes[J]. Diabetol Int, 2021, 13(1): 117-123.
[29]	BLAU J E, BAUMAN V, CONWAY E M, et al. Canagliflozin triggers the FGF23/1, 25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study[J]. JCI Insight, 2018, 3(8): e99123. DOI: 10.1172/jci.insight.99123.
[30]	BILEZIKIAN J P, WATTS N B, USISKIN K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin[J]. J Clin Endocrinol Metab, 2016, 101(1): 44-51. doi: 10.1210/jc.2015-1860
[31]	ZHUO M, HAWLEY C E, PAIK J M, et al. Association of sodium-glucose cotransporter-2 inhibitors with fracture risk in older adults with type 2 diabetes[J]. JAMA Netw Open, 2021, 4(10): e2130762. DOI: 10.1001/jamanetworkopen.2021.30762.
[32]	FRALICK M, KIM S C, SCHNEEWEISS S, et al. Fracture risk after initiation of use of Canagliflozin: a cohort study[J]. Ann Intern Med, 2019, 170(3): 155-163. doi: 10.7326/M18-0567
[33]	THRAILKILL K M, BUNN R C, UPPUGANTI S, et al. Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of bone[J]. Bone, 2020, 133: 115254. DOI: 10.1016/j.bone.2020.115254.
[34]	GERBER C, WANG X, DAVID V Q, et al. Long-term effects of SGLT-2 deletion on bone and mineral metabolism in mice[J]. JBMR Plus, 2021, 5(8): e10526. DOI: 10.1002/jbm4.10526.
[35]	BAMBA R, OKAMURA T, HASHIMOTO Y, et al. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice[J]. J Cachexia Sarcopenia Muscle, 2022, 13(1): 574-588. doi: 10.1002/jcsm.12814
[36]	YAMAKAGE H, TANAKA M, INOUE T, et al. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: a randomized, controlled trial[J]. J Diabetes Investig, 2020, 11(3): 653-661. doi: 10.1111/jdi.13179
[37]	JI L L, YEO D. Mitochondrial dysregulation and muscle disuse atrophy[J]. F1000 Res, 2019, 8: 1621. doi: 10.12688/f1000research.19139.1
[38]	OKAMURA T, HASHIMOTO Y, OSAKA T, et al. The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1[J]. J Clin Biochem Nutr, 2019, 65(1): 23-28. doi: 10.3164/jcbn.18-114
[39]	NAMBU H, TAKADA S, FUKUSHIMA A, et al. Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure[J]. European J Pharmacology, 2020, 866: 172810. DOI: 10.1016/j.ejphar.2019.172810.
[40]	XU L, NAGATA N, NAGASHIMADA M, et al. SGLT-2 inhibition by Empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice[J]. EBioMedicine, 2017, 20: 137-149. doi: 10.1016/j.ebiom.2017.05.028
[41]	PAN L, XIE W, FU X, et al. Inflammation and sarcopenia: a focus on circulating inflammatory cytokines[J]. Exp Gerontol, 2021, 154: 111544. doi: 10.1016/j.exger.2021.111544
[42]	NAZNIN F, SAKODA H, OKADA T, et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice[J]. European J Pharmacol, 2017, 794: 37-44. doi: 10.1016/j.ejphar.2016.11.028
[43]	TAKEDA K, ONO H, ISHIKAWA K, et al. Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats[J]. BMJ Open Diabetes Res Care, 2021, 9(1): e002104. DOI: 10.1136/bmjdrc-2020-002104.